COMMUNIQUÉS West-GlobeNewswire

Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
15/04/2019
NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
15/04/2019
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that the U.S. [...]
Share buy-back week 15/2019
15/04/2019
Announcement 15 April 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling [...]
ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada
15/04/2019
ChromaDex flagship Tru Niagen (nicotinamide riboside) product now available in Showcase specialty retail stores in Canada LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the [...]
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
15/04/2019
- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains rights to the eligible Rare Pediatric Disease [...]
RavenQuest Completes First Cannabis Shipment to Wayland Group
15/04/2019
VANCOUVER, British Columbia, April 15, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “ Company ” or “ RavenQuest ”) a federally licensed producer of cannabis, is pleased to [...]
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation
15/04/2019
Demonstrated statistically significant reduction in daily smoking compared to active comparator (p=0.0016) Trial conducted in collaboration with Duke University NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Axsome [...]
TLC Announces Positive End-of-Phase II Meeting with FDA for TLC599 in Knee Osteoarthritis
15/04/2019
Expects to initiate a single pivotal Phase III trial in mid-2019 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 15, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical [...]
Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
15/04/2019
SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple [...]
RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY
15/04/2019
RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY Milan, 15 April 2019 – Recordati S.p.A. will be hosting a meeting with the financial community on: Thursday 9 May at 10:30 am GMT (Registration at 9:30 am GMT) London Stock [...]
Wildflower et son rôle dans l'essor du marché du CBD présentés dans une publication de NetworkNewsWire
15/04/2019
NEW YORK, 15 avr. 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) a annoncé aujourd'hui son apparition dans une rubrique éditoriale publiée par NetworkNewsWire (« NNW »), une [...]
Communiqué de mise à disposition du Document de Référence 2018
15/04/2019
Daix (France), le 15 avril 2019 – Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de maladies dans les [...]
Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering
15/04/2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HONG KONG, April 15, 2019 ( [...]
Santhera to Present Long-term Efficacy Results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Conference
15/04/2019
Pratteln, Switzerland, April 15, 2019 - Santhera Pharmaceuticals (SIX: SANN) and its collaborating clinical experts present results of long-term efficacy on respiratory function outcomes in idebenone-treated patients [...]
AroCell and Corgenix establish the measurement of Thymidine Kinase 1 using AroCell TK 210 ELISA in a CLIA-lab in the USA
15/04/2019
AroCell AB (AROC NASDAQ Stockholm) announce today, in collaboration with Corgenix (Corgenix Inc., Colorado USA) that the AroCell TK 210 ELISA kit has been validated and approved for Thymidine Kinase 1 (TK1) measurements [...]
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
15/04/2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presented In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 DDS-04 Series Cures [...]
Motif Bio Reports Fiscal Year 2018 Results
15/04/2019
NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year [...]
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
14/04/2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 DDS-04 Series Cures [...]
Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
13/04/2019
- Favorable safety and tolerability profile - Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies - Selected for inclusion in “Best of ILC” presentation - Company to host conference [...]

Pages